From Supporting Role to Center Stage: How Private Equity’s Approach to Bio is Changing [PE Now]
Adventurous VC Bets for Big Wins Are Fading
Private Equity Picks Companies with Strong Technology and Cash Flows
Operational Efficiency, Not Just Buy-and-Sell Margins, Drives Success
IMM Private Equity, a private equity fund (PEF) management company, secured the exclusive negotiation rights for the sale of CGBio, a regenerative medicine subsidiary of Daewoong Group, earlier this month. The 51% stake held by Aihana, CGBio's largest shareholder, is up for sale. Considering that CGBio’s corporate value is estimated at around 1 trillion won, the deal size is projected to be about 600 billion won. While this deal is primarily seen as part of Daewoong Group’s governance restructuring—since the group directly sought a buyer without an external advisor—it is also being interpreted as reflecting a new trend in the private equity market.
Bio, Once the Domain of Venture Capital, Now Being Screened by Private Equity
For a long time, bio investments were considered the exclusive domain of venture capital (VC). Even without guaranteed results, it was possible to attract investments and go public on the basis of technology and growth potential alone. According to the Korea Venture Capital Association, from 2018 to 2020, the bio and healthcare sector ranked first in new VC investment share. However, after the pandemic, as overvaluations were corrected and trust in bio companies wavered in the capital markets, the proportion of VC investment in the sector also declined. Private equity funds have stepped in to fill that gap. In 2022 alone, management control of companies like Classys, Medipost, and LabGenomics was transferred to private equity funds.
The core reason private equity funds previously shunned the bio sector is simple: new drug development takes a long time and outcomes are difficult to predict. However, the bio companies now attracting private equity interest are different. These are firms in medical devices, regenerative medicine, and contract manufacturing (CMO) that have clear technological advantages, competitive strength, and stable cash flows. CGBio is a prime example. A private equity industry insider commented, “For private equity funds, which have traditionally preferred companies with strong cash flows, bio investments were seen as high-risk and speculative,” but added, “There is a growing trend of private equity funds supplying capital and supporting the growth of bio companies.”
CGBio holds the top domestic market share in bone substitute materials, achieving annual sales of 200 billion won and estimated EBITDA of 40 to 50 billion won. The global bone substitute market is estimated to be worth 6 trillion won. The company is currently awaiting approval from the US Food and Drug Administration (FDA), and industry insiders see a high probability of approval. CGBio plans to expand into major markets such as China in the future. IMM PE believes that if global approval for the bone substitute division becomes visible, CGBio’s corporate value could conservatively reach between 2 trillion and 3 trillion won.
'Buy Low, Sell High' Era Is Over... Post-Acquisition Management Becomes Key
New money moves are also being observed in the bio investment market. While overall global and domestic VC investment in bio is rebounding in terms of total volume, the number of deals is shrinking, with capital increasingly concentrated in a small number of companies, intensifying polarization. Seed-stage investment is rapidly declining, and it has become difficult to attract funding based solely on uncertain technological potential. Paradoxically, this creates favorable conditions for private equity funds to select high-quality assets for buyout (management control acquisition).
However, the industry now believes that the era of simply buying undervalued bio companies is over. The traditional private equity formula was to “buy low and sell high.” The influx of undervalued assets after the bio bubble burst in 2022 triggered private equity’s entry into the sector, which can be seen as part of this trend. However, there is a growing consensus within the private equity industry that this formula alone is no longer sufficient.
An investment banking industry insider commented, “Rather than just acquiring cheap or undervalued companies, you need to look at the trend as one where the focus is on acquiring companies with strong fundamentals and maximizing value through post-acquisition management.” In other words, profits must now be generated through management after the acquisition, not just from the price gap between acquisition and exit. Key competitive strengths now include post-deal capabilities such as production and supply chain efficiency, global expansion roadmap strategies, and improving EBITDA structure.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Global funds are also showing high expectations for Korean bio companies. BlackRock, the world’s largest asset manager, recently acquired a 5% stake in HLB, becoming its second-largest shareholder. Global pharmaceutical companies Eli Lilly and Roche have each announced plans to invest about 700 billion won in Korean bio firms. The revaluation of K-Bio’s worth is further reinforcing the rationale for private equity entry into the sector.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.